In this study, we investigated the effects and mechanism of highly expressed HSD17B13 on the pathogenesis of NAFLD and validated whether HSD17B13 is a potential target for the development of drugs to treat NAFLD. This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatotic liver disease.